reSET® and reSET-O® as treatments for substance use and opioid use disorders

Yuri Maricich, MD
Chief Medical Officer
Pear Therapeutics
Disclaimers and Important Information

- This presentation is intended for a payor and is not intended for use by healthcare professionals. The data was prepared by Pear Therapeutics, Inc. ("Pear")

- The data presented here includes unpublished "data on file"

- This presentation does not include all the necessary information for the safe and effective use of reSET® or reSET-O®. Disease state information provided is of a general nature regarding disease states and reflects information provided in the referenced publication only

- The information is in no way intended to imply or suggest any claims regarding reSET® or reSET-O® beyond their cleared indications and uses and FDA-required labeling

- The information is provided to you for review purposes only and is only intended for your use to assist you in the evaluation of Pear’s products for inclusion on your formulary and/or reimbursement for Pear’s products

- This presentation is not intended for use by individuals outside of this audience

- This presentation contains information that is confidential and proprietary to Pear and should not be shared without Pear’s prior written consent

- The speaker is an employee of Pear Therapeutics, Inc
SUD/OUD Background And Behavioral Treatment Approaches
Substance Use Disorder Is Common and Overdose Deaths are Increasing

- An estimated 20.4 million people in the US had a SUD in 2019¹

- For the year ending in August 2020, provisional data from the Centers for Disease Control and Prevention show that overdose deaths have increased 26.8 percent compared to the previous 12 months, to more than 88,000 deaths²

- 49% increase in psychostimulant overdose deaths in the year ending January 2021 in comparison to the year ending January 2020³

- 11% of individuals 26 years of age or older with a substance use disorder received any substance use treatment in 2019¹

- There are no pharmacological treatments approved for stimulant use disorder

---


---

### Substance Use Disorder by Type

<table>
<thead>
<tr>
<th>Substance</th>
<th>Number of People with Specific Past Year SUD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol</td>
<td>14.5M</td>
</tr>
<tr>
<td>Illicit Drug</td>
<td>8.3M</td>
</tr>
<tr>
<td>Marijuana</td>
<td>4.8M</td>
</tr>
<tr>
<td>Pain Reliever</td>
<td>1.4M</td>
</tr>
<tr>
<td>Methamphetamine</td>
<td>1.0M</td>
</tr>
<tr>
<td>Cocaine</td>
<td>1.0M</td>
</tr>
<tr>
<td>Stimulant</td>
<td>558,000</td>
</tr>
<tr>
<td>Heroin</td>
<td>438,000</td>
</tr>
</tbody>
</table>

---

No Past Year SUD 254.8 Million People (92.6%)

Past Year SUD 20.4 Million People (7.4%)
Opioid Use Disorder (OUD) Is An Ongoing Crisis

OUD is an increasingly common condition in the US:
- Approximately 2 million individuals in the US had an OUD in 2019
- Opioid associated deaths increased by 38% in the year ending in January 2021 compared to the year ending in January 2020

OUD is driving a growing number of deaths

January 12-Month-ending National Drug Overdose Deaths Involving Any Opioid

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>28986</td>
</tr>
<tr>
<td>2016</td>
<td>33531</td>
</tr>
<tr>
<td>2017</td>
<td>43691</td>
</tr>
<tr>
<td>2018</td>
<td>47549</td>
</tr>
<tr>
<td>2019</td>
<td>46996</td>
</tr>
<tr>
<td>2020</td>
<td>51018</td>
</tr>
<tr>
<td>2021</td>
<td>70456</td>
</tr>
</tbody>
</table>

California faces a serious public health crisis with the opioid epidemic

California Quick Stats¹

5,363*
Deaths Related to Any Opioid Overdose, 2020

3,857*
Deaths Related to Fentanyl Overdose, 2020

15,664
ED Visits Related to Any Opioid Overdose, 2020

14,867,426
Prescriptions for Opioids, 2020

*Preliminary death data

California’s MAT Expansion Efforts

California has included evidence-based behavioral therapy as an integral component of its approach to medication assisted treatment (MAT) expansion²

Behavioral treatment approach landscape

**Community Reinforcement Approach (CRA):**
- Focuses on managing behavior related to substance use, to help patients adopt a healthier lifestyle without alcohol or drug use
- Psychosocial support to support behavioral change and emotional wellbeing

**Cognitive-Behavioral Therapy (CBT) for SUD:**
- Helps patients learn to identify and correct behaviors that lead to substance use
- Helps patients learn how to deal with problems related to substance use and teaches strategies to encourage abstinence
- Each lesson ends with Fluency Training to promote learning and improve retention

**Contingency Management (CM):**
- An evidence-based adjunct to counseling that uses positive reinforcement to support treatment goals
- Offers rewards for desired behaviors, designed to weaken drug use by helping replace the ‘reward’ patients previously received from substance use

---

**US Treatment Facilities Therapeutic Approach offerings**

<table>
<thead>
<tr>
<th>Approach</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Substance abuse counseling</td>
<td>99%</td>
</tr>
<tr>
<td>Relapse prevention</td>
<td>96%</td>
</tr>
<tr>
<td>Cognitive-Behavioral therapy</td>
<td>94%</td>
</tr>
<tr>
<td>Motivational interviewing</td>
<td>93%</td>
</tr>
<tr>
<td>Anger Management</td>
<td>83%</td>
</tr>
<tr>
<td>Brief Intervention</td>
<td>82%</td>
</tr>
<tr>
<td>Trauma Counseling</td>
<td>79%</td>
</tr>
<tr>
<td>12-step facilitation</td>
<td>73%</td>
</tr>
<tr>
<td>Contingency management</td>
<td>56%</td>
</tr>
<tr>
<td>Dialectical behavioral therapy</td>
<td>54%</td>
</tr>
<tr>
<td>Rational emotive behavioral therapy</td>
<td>46%</td>
</tr>
</tbody>
</table>

---

Some evidence-based practice treatment approaches are difficult to provide for patients in an outpatient setting.

---

3. David, D. The Community Reinforcement Approach An Update of the Evidence Front Psychiatry. 2018
Contingency Management (CM) as a Behavioral Treatment Approach

What is Contingency Management?
Positive reinforcement system, in which, financial or non-financial incentives are provided contingent on performing behaviors consistent with treatment

Strong evidence base in stimulant and opioid use disorder
CM has a broad evidence base and support from systematic meta-analyses:
• An analysis of studies using guideline recommended psychosocial interventions for stimulant use disorder found contingency management to be the only intervention associated with a significant reduction in stimulant use¹
• CM was associated with a medium-large effect size in promoting abstinence from opioid use and medication adherence in treatment as usual controlled trials²

Challenges to Implementation
Scaling of CM to the broad treatment community has been challenged by lack of resources and restrictive legislation
• Delivery of CM rewards is resource intensive in community treatment clinics
• Centers for Medicare and Medicaid Services have been reluctant to allow Medicare funds to be used for CM
• California is seeking to include CM services as a benefit under Medi-Cal in SB-110³

References:

PDTs For The Treatment Of SUD/OUD
Prescription Digital Therapeutics (PDTs) Are a New Class of Therapies That Treat Serious Diseases

- PDTs meet regulatory requirements related to clinical data for safety and effectiveness and require FDA authorization

- PDTs have the potential to safely expand access to evidence-based therapies, which is highly relevant in the context of limited access to clinicians

- Mental health and wellness apps do not require FDA authorization for use:
  - Lack peer-reviewed evidence of feasibility or efficacy; only 2% supported by original publications\(^1\)
  - Have a median 15-day and 30-day retention rate of 3.9% and 3.3%, respectively\(^2\)

---

reSET and reSET-O are PDTs That Deliver Treatment for Substance Use Disorder and Opioid Use Disorder

**reSET Product Description**

- **reSET®** is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients ≥18 years of age enrolled in outpatient treatment for substance use disorder (SUD) under the supervision of a clinician.
- Based on the Therapeutic Education System (TES).
- Comprised of 61 interactive modules: 31 core modules and 30 supplemental modules.
- Core modules focus on key CRA concepts, building skills to support behavior change and prevent relapse.
- Supplemental modules provide more in-depth information on specific topics relevant to patients with SUD.

**reSET-O Product Description**

- **reSET-O®** is intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients ≥18 years of age who are currently under the supervision of a clinician.
- Based on the Therapeutic Education System (TES).
- Comprised of 67 interactive modules: 31 core modules and 36 supplemental modules.
- Core modules focus on key CRA concepts, building skills to support behavior change and prevent relapse.
- Supplemental modules provide more in-depth information on specific topics relevant to patients with OUD.
- Voluntary buprenorphine check-in feature to support buprenorphine use.
### Community Reinforcement Approach (CRA)\(^1,2,3\)

- A comprehensive CBT package that a special focus on helping people Substance Use Disorders (SUDs) discover and adopt pleasurable and healthy lifestyles that are more rewarding than using alcohol or drugs
- CRA is among the most strongly supported behavioral therapies for SUDs and has been effective in treatment across a variety of different substances of abuse

### Fluency Training\(^4\)

- Individually-paced presentation of content and testing to facilitate and confirm mastery of learning
- Demonstrated to promote learning and improve both short-term and long-term retention of material

### Contingency Management (CM)\(^5,6\)

- Evidence-based positive reinforcement system, in which, financial or non-financial incentives are provided contingent on performing behaviors consistent with treatment
- Efficacy of Contingency Management has been demonstrated across a wide range of SUDs

---

reSET and reSET-O Mechanisms of Action

reSET and reSET-O Have Three Primary Mechanisms of Action

Community Reinforcement Approach (CRA) Lessons

Fluency Training

Contingency Management (CM)
### Pivotal Trial Overview

399 patients with SUD (alcohol, cannabis, cocaine, stimulants) received either:
- Treatment-as-Usual (TAU), consisting of intensive face-to-face therapy
- Reduced TAU and reSET (rTAU + reSET®) for 12 weeks

Patients provided urine samples twice per week to objectively monitor abstinence

Co-primary study endpoints
- Abstinence in weeks 9-12
- Retention in treatment

### Study Results

- **Abstinence: all patients**
  - TAU: 17.6% (n=193)
  - rTAU + reSET®: 40.3% (n=206)
  - **P-value:** 0.0004

- **Abstinence: non-abstinent at study start**
  - TAU: 3.2% (n=91)
  - rTAU + reSET®: 16.1% (n=101)
  - **P-value:** 0.0013

- **Retention in treatment: all patients**
  - TAU: 63.2%
  - rTAU + reSET®: 76.2%
  - **P-value:** 0.0042

---

170 patients were randomized to receive either:

- Treatment-as-Usual (TAU), consisting of Contingency Management + buprenorphine¹ or
- TAU + reSET-O® (academic name Therapeutic Education System, or TES) + Contingency Management + buprenorphine

All patients received 30 mins. of face-to-face counseling every other week.

Patients provided urine samples 3x per week to objectively monitor abstinence.

Co-primary endpoint analysis²

- Abstinence/Negative urine drug screens in weeks 9-12
- Retention in treatment

---

Study Results¹
Retirement in Treatment

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Total</th>
<th>Event</th>
<th>Median (95% CI)</th>
<th>HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAU</td>
<td>79</td>
<td>26</td>
<td>NE (NE-NE)</td>
<td>0.49 (0.26-0.92)</td>
</tr>
<tr>
<td>TES</td>
<td>91</td>
<td>16</td>
<td>NE (NE-NE)</td>
<td>0.0224</td>
</tr>
</tbody>
</table>

Logrank P-value: 0.0224

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>TAU + reSET-O®</th>
<th>TAU</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstinence (Opioids)</td>
<td>77.3% (n=91)</td>
<td>62.1% (n=79)</td>
<td>0.0248</td>
</tr>
<tr>
<td>Retention (All)</td>
<td>82.4%</td>
<td>68.4%</td>
<td>0.0224</td>
</tr>
</tbody>
</table>


² Co-primary endpoint analysis

---

PROPERTY OF PEAR THERAPEUTICS, INC. PROPRIETARY AND NONTRANSFERABLE. FOR CAADPE ONLY. CONFIDENTIAL AND NOT FOR DISTRIBUTION. © 2021 Pear Therapeutics, Inc. All rights reserved. reSET®, reSET-O® and Pear Therapeutics® are the trademarks of Pear Therapeutics, Inc.
Real-world use and clinical outcomes after 24 weeks of treatment with a prescription digital therapeutic for opioid use disorder

https://doi.org/10.1080/21548331.2021.1974243
reSET-O is intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.

**IMPORTANT SAFETY INFORMATION**

The duration of the prescription is 12 weeks (84 days). Additional 12-week (84 day) access intervals to the reSET-O prescription digital therapeutic may benefit patients, as OUD is a chronic disease; however, the benefits of prescription extension have not been evaluated.
Background and Objectives
A Continuum of Evidence for reSET-O to Support Clinical Use, Policy and Decision Making

Randomized Clinical Trials (RCTs)
Demonstrate gold-standard scientific validity using objective endpoints

Real-World Evidence (RWE)
Confirm generalizability & external validity of RCTs in broad real-world use

Health Economics and Outcomes Research (HEOR)
Correlate economic outcomes with clinical value to support providers and payers
Objectives

Evaluate patient engagement with the PDT as well as rates of opioid use and retention among a geographically diverse population of patients prescribed a second prescription and treated for 24 weeks

The duration of a reSET-O prescription is 12 weeks (84 days). Some providers may opt to prescribe additional 12-week (84 day) access intervals to the reSET-O prescription digital therapeutic, as opioid use disorder is a chronic disease; however, the benefits of prescription extension have not been evaluated.

reSET-O Clinician Directions for Use. Pear Therapeutics. 2020
Methods
Population and Data Collection

- Real-world observational evaluation of population who accessed first and subsequent reSET-O prescriptions and completed at least one lesson
  - Under the care of clinicians across 12 states
  - Prescribed reSET-O by their clinician as part of their overall standard of care
    - Completed first prescription between 1/1/2019 and 12/31/2020
  - Broad range of treatment settings and organizations
  - All patients were diagnosed with OUD and were being treated with buprenorphine MOUD at clinician determined doses, routes of administration, and regimens
  - The dose, or unit of treatment, is a module or therapy lesson, with patients instructed to complete four per week
  - Patient interaction with the PDT and other therapeutic use data (de-identified and patient consented via terms of service agreement) were collected and analyzed
  - Substance use was evaluated as a composite of patient self-reports recorded via the PDT, and in clinic urine drug screens (UDS) that were recorded by clinicians

Health Care Resource Utilization (HCRU)

- A retrospective analysis of health insurance claims (HealthVerity PrivateSource 20 claims database) was performed to assess the impact of PDT use among patients who completed a single (12 week) prescription vs. those who completed a second (24 week) prescription

Endpoints

Primary Endpoint
• Abstinence over the final 4 weeks of the 12-week reSET-O prescription (weeks 9-12)
  – Defined as no positive urine drug screen (UDS) and/or self-reported use last 4 weeks

Secondary Endpoint
• Treatment Responder Rate
  – Defined as patients with ≥ 80% negative UDS and/or self-reported opioid non-use over the 12-week reSET-O prescription
  – Patients were pushed a self-report assessment every 4 days, but are not required to complete the assessment

Additional Endpoints
• Engagement and use of reSET-O
  – Module completion, active days, activity by week, etc.
  – Activity was defined as patient use of any PDT feature on a given day
• Retention over the last 4 weeks of the 12-week reSET-O prescription (weeks 9-12)
  – Defined as any patient activity in the digital therapeutic over the last 4-weeks of treatment
• Association of abstinence/opioid use and retention outcomes with early therapeutic use (weeks 1-4)

https://doi.org/10.1080/21548331.2021.1974243
For purposes of the evaluation of the outcome of abstinence in this RWE analysis, abstinence was defined using the endpoints of urine drug screen (UDS) and/or self report, under the approach defined below. As real-world-data, there was no defined schedule for collecting UDS. UDS was collected and entered at the discretion of the clinician. Self-report was collected via pushed assessment in reSET-O.

Primary Endpoint: Abstinence over the final 4 weeks of the 12-week reSET-O prescription (weeks 9-12) assessed using two imputation methods is reported¹

**Imputation Method**

<table>
<thead>
<tr>
<th>Missing Data Positive</th>
<th>Missing Data Removed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>For weeks 9-12:</strong></td>
<td></td>
</tr>
<tr>
<td>Patients without any data (UDS or self-reports) over the final four weeks of reSET-O prescription assumed non-abstinent/positive in analysis</td>
<td>Patients without any data (UDS or self-reports) over the final four weeks of reSET-O prescription removed from analysis population</td>
</tr>
</tbody>
</table>

Health Care Resource Utilization

• A retrospective analysis of health insurance claims (HealthVerity PrivateSource 20 claims database) was performed to assess the impact of PDT use among patients who completed a single (12 week) prescription vs. those who completed a second (24 week) prescription

• Evaluated incidence of unique hospital encounters including emergency department, observation, inpatient, intensive care unit, and partial hospitalizations over 9 months following the initiation of the first prescription (index date)

• Incidence and incidence rate ratios were evaluated from a negative binomial model of encounters, with an offset for the number of days in the post-index period and adjusted for age, gender, and pre-index unique hospital encounters

• Minimum of 12 weeks continuous eligibility was required

https://doi.org/10.1080/21548331.2021.1974243
Results
A Large All-comer Population Produced Evaluable Data from First and Second Prescriptions

Real-world observational evaluation of a population that completed at least one lesson of first, and subsequent reSET-O prescriptions

First prescription (12-weeks); Missing data positive abstinence imputation (N=3,817)

- n=2,733 included in missing data removed abstinence imputation

Second prescription (24-weeks); Missing data positive abstinence imputation (N=643)

- n=584 included in missing data removed abstinence imputation

Patients available for health care resource utilization analysis

- ≥12 weeks of pharmacy enrollment before and after the index date (1/1/2019-12/8/2019): N = 424
- Patients with only 1 prescription: N=324
- Patients with only 2 prescriptions: N=103

Patients Were Represented Across Age Groups and Gender

**Representation by Age**

Mean age 39 years

**Representation by Gender**


*Proportion of population that did not provide data on gender.
Activity and Module Completion Across Age Categories

Active Days by Age

<table>
<thead>
<tr>
<th>Age</th>
<th>Median Active Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>19-29</td>
<td>19</td>
</tr>
<tr>
<td>30-39</td>
<td>24</td>
</tr>
<tr>
<td>40-49</td>
<td>27</td>
</tr>
<tr>
<td>50-59</td>
<td>24</td>
</tr>
<tr>
<td>60+</td>
<td>21</td>
</tr>
</tbody>
</table>

Modules Completed by Age

<table>
<thead>
<tr>
<th>Age</th>
<th>Median Modules Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>19-29</td>
<td>24</td>
</tr>
<tr>
<td>30-39</td>
<td>29</td>
</tr>
<tr>
<td>40-49</td>
<td>37</td>
</tr>
<tr>
<td>50-59</td>
<td>39</td>
</tr>
<tr>
<td>60+</td>
<td>23</td>
</tr>
</tbody>
</table>

Activity was defined as patient use of any PDT feature on a given day.

A Majority of Patients Completed at Least Half of Core Modules in First and Subsequent Prescriptions

Core Module Completion

<table>
<thead>
<tr>
<th>Module Completion</th>
<th>12 Weeks (N=3817)</th>
<th>24 Weeks (N=643)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Completed a Module</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Completed 8+ Core Modules</td>
<td>79%</td>
<td>93%</td>
</tr>
<tr>
<td>Completed 50% of Core Modules</td>
<td>65%</td>
<td>85%</td>
</tr>
<tr>
<td>Completed All Core Modules</td>
<td>48%</td>
<td>64%</td>
</tr>
</tbody>
</table>

A Majority of Patients Remain Active in reSET-O Through Week 12 of First and Second Prescriptions

Activity by Week

12 Weeks (N=3817) 24 Weeks (N=643)

Activity was defined as patient use of any PDT feature on a given day

Patients are active in reSET-O Throughout the Full 24-hour Period

Activity by Time of Day

- In each cohort approximately 60% of activity occurred during typical clinic hours
- Approximately 40% of activity occurred when treatment may be otherwise unavailable

Activity was defined as patient use of any PDT feature on a given day
Responder Rate of Greater than 80% was Observed in the First and Second Prescription

Responder Rate
(≥80% Negative Self-report or Urine Drug Screen for the 12-week Duration)

Pivotal Study¹ (N=91)
85%

12 Weeks (N=3817)
88%

24 Weeks (N=643)
94%

Analysis Set

Patients are pushed a self report assessment every 4 days, but are not required to complete the assessment

Responders Rate for each group defined as:

Pivotal Study: ≥80% negative UDS and/or self-reported non-use across the 12-week pivotal study
RWE: ≥ 80% negative UDS and/or self-reported non-use over the 12-week reSET-O prescription

High Rates of Abstinence Were Observed in the First and Second Prescription

Analyses of “Abstinence” for each group:

Pivotal Study: Urine drug screen (UDS) for opioids collected 3 days per week over the final four study weeks (weeks 9-12), patients who missed samples assumed positive;

Missing Data Positive: No positive UDS and/or self-reported use over the final 4 weeks of the 12-week reSET-O prescription (weeks 9-12); Patients without any data (UDS or self-reports) over the final four weeks assumed non-abstinent/positive in analysis

Missing Data Removed: No positive UDS and/or self-reported use over the final 4 weeks of the 12-week reSET-O prescription (weeks 9-12); Patients without any data (UDS or self-reports) over the final four weeks removed from analysis population


A Majority of Patients Were Retained in Treatment in the First and Subsequent Prescriptions

Retention Rate for each group defined as:

Pivotal Study: Patients remaining in treatment at 12 week study end
RWE: Any patient activity within the digital therapeutic during the last 4-weeks of the prescription

Module completion during the first four weeks and abstinence during the last four weeks of the prescription

Analyses of “abstinence” conducted with the missing data positive imputation in those completing up to the recommended dose (4 lessons) of therapy in the first 4 weeks of treatment. Minimum number of modules completed represents the lowest number of lessons a patient completed in a week during weeks 1-4 of the prescription.

**Missing Data Positive:** No positive urine drug screen (UDS) and/or self-reported use over the final 4 weeks of the 12-week reSET-O prescription (weeks 9-12); Patients without any data (UDS or self-reports) over the final four weeks assumed non-abstinent/positive in analysis


**Minimum Number of Modules Completed in a Week During the First 4 Weeks of the Prescription**

<table>
<thead>
<tr>
<th>Week</th>
<th>Min. Modules</th>
<th>0%</th>
<th>20%</th>
<th>40%</th>
<th>60%</th>
<th>80%</th>
<th>100%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>298</td>
<td>74%</td>
<td>82%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>221</td>
<td>79%</td>
<td>84%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>210</td>
<td>85%</td>
<td>94%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>977</td>
<td>88%</td>
<td>91%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

n= 1988, 204, 298, 56, 221, 50, 210, 51, 977, 267
Module Completion During The First Four Weeks And Retention During The Last Four Weeks Of The Prescription

Retention Rate in those completing up to the recommended dose (4 lessons) of therapy in the first 4 weeks of treatment.
Minimum number of modules completed represents the lowest number of lessons a patient completed in a week during weeks 1-4 of the prescription.
Retention defined as any patient activity within the digital therapeutic during the last 4-weeks of treatment.

https://doi.org/10.1080/21548331.2021.1974243
Incidence of Unique Hospital Encounters Was Observed to be Lower in Patients With a Second reSET-O Prescription

### Unique Hospital Encounters
- Inpatient stays
- ICU stays
- Emergency department visits
- Partial hospitalizations
- Observation visits

<table>
<thead>
<tr>
<th></th>
<th>reSET-O</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 Script</td>
</tr>
<tr>
<td>(n=324)</td>
<td>(n=103)</td>
</tr>
<tr>
<td><strong>Incidence Rate (95% CI)</strong></td>
<td>0.63</td>
</tr>
<tr>
<td></td>
<td>(0.49, 0.80)</td>
</tr>
<tr>
<td><strong>% Reduction</strong></td>
<td>Reference</td>
</tr>
</tbody>
</table>

**FDA has not found reSET-O® safe or effective for prescriptions beyond the first 12 weeks**

reSET-O® has not been shown to impact patient and health system costs in prospective, randomized, clinical trials

   [https://doi.org/10.1080/21548331.2021.1974243](https://doi.org/10.1080/21548331.2021.1974243)
Limitations and Conclusions
Limitations

• Evaluation of real-world data is collected in an environment that is not as stringently controlled as a randomized controlled trial derived data

• Data is derived from a mixed population of patients who were at various stages of treatment

• Abstinence outcomes are based on composite of patient self-reports and/or objective urine drug screens (UDS)

• Activity in the application may not reflect full engagement with the therapeutic content of reSET-O

https://doi.org/10.1080/21548331.2021.1974243
Conclusions

First published data on real-world clinical outcomes over a 24-week period:

• Patients with opioid use disorder had higher engagement with a second prescription of a PDT in comparison to patients with first prescription

• Patients with 24 weeks of reSET-O treatment showed durable and high levels of self-reported abstinence and treatment retention

• Patients with 24 weeks of reSET-O treatment had a lower rate of unique hospital encounters compared to those treated for 12 weeks


reSET-O is not authorized to improve abstinence.
Therapeutic use of reSET-O in California
What has been done in California to date?

- Demonstrated provider and patient demand for reSET-O within California
  - 174 patients have used reSET-O
  - 11 providers writing prescriptions

- Demonstrated strong engagement with reSET-O
  - Data from California patients at completion of their first prescription (N=174)
    - 45% of patients were active in the therapeutic in week 12
    - 86% of patients engaged during non-clinic hours (7pm-9am)
    - 30% of patients completed all core treatment modules

Data from patients that were prescribed reSET-O prescription between 1/1/2019 and 9/1/2021 and completed at least 1 lesson
reSET-O® Health Care Resource Utilization and Cost Impact Analysis

A 6-month and 9-month Claims Analysis
Utilize a retrospective study design to understand the impact of reSET-O prescribing on healthcare resource utilization in patients with opioid use disorder

- The retrospective design allows patients exposed to reSET-O to act as their own controls
- Gaining an understanding of the population impact of reSET-O under usual care conditions
Limitations

• Real world evidence lacks randomization and therefore may produce results influenced by selection bias

• The majority of patients identified were Medicaid patients; thus, the results may not generalize to all populations

• Health care resource utilization in the pre-index period may be increased prior to intensification of treatment with reSET-O

• The pre-index and post-index period differed substantially in assessed duration
A 6-month Claims Database Analysis of Healthcare Resource Utilization Before and After reSET-O in Patients With Opioid Use Disorder

A retrospective analysis of the HealthVerity PrivateSource 20 claims database was performed to assess the impact of reSET-O initiation on healthcare resource utilization among patients receiving treatment for opioid use disorder.

**Patient Identification**
Patients who activated reSET-O between January 2019 and October 2019 from a large, nationally representative database.

**Data Collection**

- **BASELINE PERIOD**
  - 6 Months Pre-index

- **STUDY PERIOD**
  - 6 Months Post-index

**INDEX DATE**
Date of first prescription for reSET-O

**Analysis**
Comparison of HRU between baseline and study periods, including:
- All facility services
- All clinician services

reSET-O has not been shown or indicated to impact patient and health system cost in prospective, randomized, clinical trials.

PEAR THERAPEUTICS data on file

PROPERTY OF PEAR THERAPEUTICS, INC. PROPRIETARY AND NONTRANSFERABLE. FOR CAADPE ONLY. CONFIDENTIAL AND NOT FOR DISTRIBUTION. © 2021 Pear Therapeutics, Inc. All rights reserved. reSET®, reSET-O® and Pear Therapeutics® are the trademarks of Pear Therapeutics, Inc.
Patients Were Largely Buprenorphine Adherent Medicaid Recipients

<table>
<thead>
<tr>
<th>Demographics</th>
<th>N=351</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age on Index Date</td>
<td></td>
</tr>
<tr>
<td>Mean, (SD)</td>
<td>37.0 (8.64)</td>
</tr>
<tr>
<td>Median, (range)</td>
<td>36.0 (20–67)</td>
</tr>
<tr>
<td>Age on Index Date, n (%)</td>
<td></td>
</tr>
<tr>
<td>18-24</td>
<td>15 (4.3%)</td>
</tr>
<tr>
<td>25-34</td>
<td>134 (38.2%)</td>
</tr>
<tr>
<td>35-44</td>
<td>145 (41.3%)</td>
</tr>
<tr>
<td>45-54</td>
<td>39 (11.1%)</td>
</tr>
<tr>
<td>55-64</td>
<td>16 (4.6%)</td>
</tr>
<tr>
<td>65-74</td>
<td>2 (0.6%)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>209 (59.5%)</td>
</tr>
<tr>
<td>Male</td>
<td>142 (40.5%)</td>
</tr>
<tr>
<td>Payer on Index Date, n (%)</td>
<td></td>
</tr>
<tr>
<td>Commercial</td>
<td>45 (12.8%)</td>
</tr>
<tr>
<td>Medicaid</td>
<td>290 (82.6%)</td>
</tr>
<tr>
<td>Medicare Advantage</td>
<td>8 (2.3%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>8 (2.3%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical Characteristics</th>
<th>N=351</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opioid use disorder in the pre-index period, n (%)</td>
<td></td>
</tr>
<tr>
<td>F11.10 Opioid abuse, uncomplicated</td>
<td>19 (5.4%)</td>
</tr>
<tr>
<td>F11.11 Opioid abuse, in remission</td>
<td>5 (1.4%)</td>
</tr>
<tr>
<td>F11.14 Opioid abuse with opioid-induced mood disorder</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td>F11.19 with unspecified opioid-induced disorder</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td>F11.20 Opioid dependence, uncomplicated</td>
<td>290 (82.6%)</td>
</tr>
<tr>
<td>F11.21 Opioid dependence, in remission</td>
<td>38 (10.8%)</td>
</tr>
<tr>
<td>F11.23 Opioid dependence with withdrawal</td>
<td>16 (4.6%)</td>
</tr>
<tr>
<td>F11.288 Opioid dependence with other opioid-induced disorder</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td>F11.29 Opioid dependence with unspecified opioid-induced disorder</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td>F11.90 Opioid use, unspecified, uncomplicated</td>
<td>8 (2.3%)</td>
</tr>
<tr>
<td>F11.988 Opioid use, unspecified with other opioid-induced disorder</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td>F11.99 Opioid use, unspecified with unspecified opioid-induced disorder</td>
<td>1 (0.3%)</td>
</tr>
<tr>
<td>No opioid use diagnosis code</td>
<td>46 (13.1%)</td>
</tr>
<tr>
<td>Buprenorphine treated Pre-Index, n (%)</td>
<td>249 (76.7%)</td>
</tr>
<tr>
<td>Buprenorphine treated Post-Index, n (%)</td>
<td>240 (72.8%)</td>
</tr>
<tr>
<td>Buprenorphine adherence Pre-Index (MPR), adjusted mean (SE)</td>
<td>0.73 (0.21)</td>
</tr>
<tr>
<td>Buprenorphine adherence Post-Index (MPR), adjusted mean (SE)</td>
<td>0.82 (0.21)</td>
</tr>
</tbody>
</table>

MPR=medication possession ratio; SD=standard deviation
Pear Therapeutics data on file

PROPERTY OF PEAR THERAPEUTICS, INC. PROPRIETARY AND NONTRANSFERABLE. FOR CAADPE ONLY. CONFIDENTIAL AND NOT FOR DISTRIBUTION. © 2021 Pear Therapeutics, Inc. All rights reserved. reSET®, reSET-O® and Pear Therapeutics® are the trademarks of Pear Therapeutics, Inc.
reSET-O Prescription May Be Associated With Reduced Utilization of Major Cost Drivers

ER=emergency department; ICU=intensive care unit
*p<0.05; †projected cost; ‡Mean number of days in the pre-index and post-index period are 180.0 and 104.0, respectively. Incidence and IRR are evaluated from a repeated measures (ie, pre- and post-index for each patient) negative binomial model of count of stays/visits, with an offset for the number of days in each period

Category costs were derived from published Medicare reimbursement costs

Pear Therapeutics data on file

PROPERTY OF PEAR THERAPEUTICS, INC. PROPRIETARY AND NONTRANSFERABLE. FOR CAADPE ONLY. CONFIDENTIAL AND NOT FOR DISTRIBUTION. © 2021 Pear Therapeutics, Inc. All rights reserved. reSET®, reSET-O® and Pear Therapeutics® are the trademarks of Pear Therapeutics, Inc.
**reSET-O Prescribing May Be Associated With an Increase in Rehabilitation Visits**

![Graph showing the impact of reSET-O on rehabilitation visits](Image)

- **Drug Testing**: -638* (-$45k)
- **Psychiatry**: -349* (-$35k)
- **Laboratory Services**: -166* (-$5k)
- **Outpatient Services**: -154 (-$12k)
- **Substance Rehab. Services**: -96 (-$5k)
- **Other Rehab. Services**: -66 (-$2k)
- **Cardiovascular Care**: -52* (-$8k)
- **Mental Health Rehab. Services**: 61 ($1k)
- **Behavioral Health Rehab. Services**: 111 ($6k)
- **Case Mgmt. Services**: 176 ($9k)
- **TOTAL**: -1234 (-$102k)

* *p<0.05; †projected cost; ‡Mean number of days in the pre-index and post-index period are 180.0 and 104.0, respectively. Incidence and IRR are evaluated from a repeated measures (ie, pre- and post-index for each patient) negative binomial model of count of stays/visits, with an offset for the number of days in each period.*

Pear Therapeutics data on file
**reSET-O Prescribing May Be Associated With Reduced Resource Utilization and Projected Cost**

<table>
<thead>
<tr>
<th>Utilization</th>
<th>Facility Encounters</th>
<th>Clinician Encounters</th>
<th>Subtotal</th>
<th>Number of Episodes (Study Population; N=351)</th>
<th>Projected Cost of Episodes (Study Population; N=351)</th>
<th>Cost Change per Patient</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reduced</strong></td>
<td>-81</td>
<td>-1760</td>
<td>-1841</td>
<td>-$627,868.20</td>
<td>-$1,788.80</td>
<td>-$2,281.05</td>
</tr>
<tr>
<td><strong>Increased</strong></td>
<td>25</td>
<td>537</td>
<td>562</td>
<td>$23,903.10</td>
<td>$68.10</td>
<td>$131.03</td>
</tr>
</tbody>
</table>

**NET IMPACT**

-1279

-$754,656.71

-$2,150.02

---

reSET-O has not been shown or indicated to impact patient and health system cost in prospective, randomized, clinical trials.

---

*Pear Therapeutics data on file*
9-month Analysis of Healthcare Resource Use Before and After reSET-O in Patients With Opioid Use Disorder

A retrospective analysis of the HealthVerity PrivateSource 20 claims database was performed to assess the impact of reSET-O initiation vs. non-initiation/non-engagement* (control group) on healthcare resource utilization among patients receiving treatment for OUD.

Data Collection

Patient Identification
Patients who activated reSET-O between January 2019 and October 2019 from a large, nationally representative database

INDEX DATE
Date of first prescription for reSET-O

STUDY PERIOD (9 Months Post-index)

9 Months Post-index reSET-O

9 Months Post-index Controls

Analysis
Comparison of HRU between baseline and study periods, including:
- All facility services
- All clinician services

reSET-O has not been shown or indicated to impact patient and health system cost in prospective, randomized, clinical trials.

HRU=healthcare resource use; OUD=opioid use disorder
*Non-initiation is defined as a reSET-O prescription that was never activated. Non-engagement is defined as an activated prescription in which patients do not complete any lessons after week 1.

Pear Therapeutics data on file
# Patients Were Largely Buprenorphine Adherent Medicaid Recipients

## Demographics

<table>
<thead>
<tr>
<th>Demographics</th>
<th>reSET-O N=444</th>
<th>Control N=64</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age on Index Date</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean, (SD)</td>
<td>37.5 (8.75)</td>
<td>39.5 (10.13)</td>
</tr>
<tr>
<td>Median, (range)</td>
<td>36.0 (20–68)</td>
<td>38.5 (21-69)</td>
</tr>
<tr>
<td>Age on Index Date, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-24</td>
<td>14 (3.2)</td>
<td>3 (4.7)</td>
</tr>
<tr>
<td>25-34</td>
<td>166 (37.4)</td>
<td>19 (29.7)</td>
</tr>
<tr>
<td>35-44</td>
<td>188 (42.3)</td>
<td>24 (37.5)</td>
</tr>
<tr>
<td>45-54</td>
<td>48 (10.8)</td>
<td>13 (20.3)</td>
</tr>
<tr>
<td>55-64</td>
<td>24 (5.4)</td>
<td>4 (6.3)</td>
</tr>
<tr>
<td>65-74</td>
<td>4 (0.9)</td>
<td>1 (1.6)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>280 (63.1)</td>
<td>21 (32.8)</td>
</tr>
<tr>
<td>Male</td>
<td>164 (36.9)</td>
<td>43 (67.2)</td>
</tr>
<tr>
<td>Payer on Index Date, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commercial</td>
<td>50 (11.3)</td>
<td>14 (21.9)</td>
</tr>
<tr>
<td>Medicaid</td>
<td>373 (84.0)</td>
<td>47 (73.4)</td>
</tr>
<tr>
<td>Medicare Advantage</td>
<td>13 (2.9)</td>
<td>1 (1.6)</td>
</tr>
<tr>
<td>Unknown</td>
<td>8 (1.8)</td>
<td>2 (3.1)</td>
</tr>
</tbody>
</table>

## Clinical Characteristics

<table>
<thead>
<tr>
<th>Clinical Characteristics</th>
<th>reSET-O N=444</th>
<th>Control N=64</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opioid Use Disorder in the Pre-index Period, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F11.10 Opioid abuse, uncomplicated</td>
<td>53 (11.9)</td>
<td>11 (17.2)</td>
</tr>
<tr>
<td>F11.11 Opioid abuse, in remission</td>
<td>14 (3.2)</td>
<td>1 (1.6)</td>
</tr>
<tr>
<td>F11.14 Opioid abuse with opioid-induced mood disorder</td>
<td>1 (0.2)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>F11.19 with unspecified opioid-induced disorder</td>
<td>1 (0.2)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>F11.20 Opioid dependence, uncomplicated</td>
<td>398 (89.6)</td>
<td>54 (84.4)</td>
</tr>
<tr>
<td>F11.21 Opioid dependence, in remission</td>
<td>58 (13.1)</td>
<td>7 (10.9)</td>
</tr>
<tr>
<td>F11.23 Opioid dependence with withdrawal</td>
<td>33 (7.4)</td>
<td>8 (12.5)</td>
</tr>
<tr>
<td>F11.288 Opioid dependence with other opioid-induced disorder</td>
<td>1 (0.2)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>F11.29 Opioid dependence with unspecified opioid-induced disorder</td>
<td>5 (1.1)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>F11.90 Opioid use, unspecified, uncomplicated</td>
<td>17 (3.8)</td>
<td>3 (4.7)</td>
</tr>
<tr>
<td>F11.988 Opioid use, unspecified with other opioid-induced disorder</td>
<td>2 (0.5)</td>
<td>1 (1.6)</td>
</tr>
<tr>
<td>F11.99 Opioid use, unspecified with unspecified opioid-induced disorder</td>
<td>9 (2.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>No opioid use diagnosis code</td>
<td>38 (8.6)</td>
<td>8 (12.5)</td>
</tr>
<tr>
<td>Buprenorphine treated Pre-Index, n (%)</td>
<td>345 (79.7)</td>
<td>43 (100.0)</td>
</tr>
<tr>
<td>Buprenorphine treated Post-Index, n (%)</td>
<td>332 (94.1)</td>
<td>42 (97.7)</td>
</tr>
<tr>
<td>Buprenorphine Adherence</td>
<td>N=324</td>
<td>N=42</td>
</tr>
<tr>
<td>Pre-Index (MPR), adjusted mean (SE)</td>
<td>0.69 (0.02)</td>
<td>0.62 (0.06)</td>
</tr>
<tr>
<td>Post-Index (MPR), adjusted mean (SE)</td>
<td>0.81 (0.02)</td>
<td>0.79 (0.06)</td>
</tr>
</tbody>
</table>

MPR=medication possession ratio; SD=standard deviation

Pear Therapeutics data on file
### Inpatient Cost Savings

<table>
<thead>
<tr>
<th>Inpatient</th>
<th>Cost/Patient reSET-O (n=444)</th>
<th>Cost/Patient Control (n=64)</th>
<th>Difference (Control minus reSET-O)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Facility Services</td>
<td>$2,693</td>
<td>$6,130</td>
<td>($3,437)</td>
</tr>
<tr>
<td>Clinician services</td>
<td>$6,040</td>
<td>$5,311</td>
<td>$729</td>
</tr>
<tr>
<td><strong>Net Cost Difference</strong></td>
<td></td>
<td></td>
<td>($2,708)</td>
</tr>
</tbody>
</table>

- Control Patients were observed to have more costs than reSET-O patients in the 9 months following prescription of reSET-O.
- There was a 46% lower rate of observed hospitalizations per patient (0.14 vs. 0.26), despite an increase in clinician services following prescription for reSET-O.

reSET-O has not been shown or indicated to impact patient and health system cost in prospective, randomized, clinical trials.

Pear Therapeutics data on file

PROPERTY OF PEAR THERAPEUTICS, INC. PROPRIETARY AND NONTRANSFERABLE. FOR CAADPE ONLY. CONFIDENTIAL AND NOT FOR DISTRIBUTION. © 2021 Pear Therapeutics, Inc. All rights reserved. reSET®, reSET-O® and Pear Therapeutics® are the trademarks of Pear Therapeutics, Inc.
Conclusions

• reSET-O prescription may be associated with reduced utilization of major cost drivers in the healthcare system

• reSET-O prescription may be associated with an increase in utilization of rehabilitation services

• Findings may indicate a potential for near-term total cost reduction
INDICATIONS FOR USE:

reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older who are currently enrolled in outpatient treatment under the supervision of a clinician. reSET is indicated as a 12-week (90 days) prescription only treatment for patients with Substance Use Disorder (SUD), who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse. reSET is intended to increase abstinence from a patient’s substances of abuse during treatment and increase retention in the outpatient treatment program.

IMPORTANT SAFETY INFORMATION

Warnings: reSET is intended for patients whose primary language is English with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

The long-term benefit of reSET has not been evaluated in studies lasting beyond 12 weeks (90 days) in the substance use disorder population. The ability of reSET to prevent potential relapse after therapy discontinuation has not been studied.

Please see the Clinician Brief Summary Instructions for reSET.
INDICATIONS FOR USE:
reSET-O is intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.

IMPORTANT SAFETY INFORMATION

Warnings: reSET-O is intended for patients whose primary language is English with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET-O is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET-O to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET-O to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner and is not intended to reduce the frequency or duration of in-person therapy. reSET-O does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.

Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with opioid use disorder have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should undertake standard of care to monitor patients for medical problems and mental health disease, including risk for harming others and/or themselves.

The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.

Please see the Clinician Brief Summary Instructions for reSET-O.